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Use of Biologics in Pityriasis Rubra Pilaris: A Case Report and Review of the Literature 
 
Huizenga T, Warbasse E. 
 
Pityriasis rubra pilaris (PRP) is an inflammatory papulosquamous disorder of unknown etiology. 
It is characterized by hyperkeratotic scaling plaques with an orange-red hue, “islands of sparing,” 
and palmoplantar keratoderma; it may cause erythroderma. There have been no completed 
controlled clinical trials for the treatment of PRP, and there are no FDA approved treatments at 
this time; most treatment evidence is derived from case reports. This review of the literature 
explores the use of various biologics which have been attempted for treatment of widespread or 
treatment resistant PRP. Some case reports have demonstrated efficacy of anti-IL-17 and anti-
IL12/23 agents for PRP treatment. IL-17, a pro-inflammatory cytokine, has been found in 
increased levels in the skin of patients with PRP, and reductions in the level of IL-17 have been 
correlated with improvement in the histopathologic findings. In this case report and review of the 
literature, the use of ixekizumab, a humanized IgG4 monoclonal antibody which selectively binds 
IL-17A and inhibits the IL-17A receptor is explored in the treatment of widespread PRP in a 63 
year old woman with treatment resistant erythrodermic PRP. 
 
